Continuous Glucose Monitoring in Intensive Care Unit to Evaluate Glucose Control After Major Surgery

What this Trial Is About

Researchers are evaluating the use of continuous glucose monitors (CGM) in patients in intensive care units (ICU) who have undergone major surgeries such as pancreas surgery, liver transplantation, or simultaneous pancreas and kidney transplantation, including those with diabetes mellitus. The study aims to determine if CGM helps maintain blood glucose within the recommended target range and to compare the accuracy of CGM sensors with standard blood glucose measurement methods. This non-commercial, randomized, open-label study is conducted to address the challenges of glucose control in ICU patients and reduce the burden on nursing staff. Participants will be randomized into two groups: one group will use an active CGM device (Dexcom G6) to guide insulin therapy, while the control group will receive standard care with blinded CGM monitoring without influencing treatment. Continuous glucose monitoring begins after surgery to avoid interference during procedures, and insulin doses will be adjusted according to the standard ICU protocol. Each surgical patient group will be randomized and analyzed independently. During the approximately 5 to 7 days in the postoperative ICU, participants will have their glucose levels continuously monitored and insulin doses recorded. Researchers will measure the time spent in the target glucose range, episodes of high or low blood sugar, glycemic variability, surgical and infectious complications, and duration of hospital stay. Blood glucose will also be measured using standard biochemistry methods. This comprehensive monitoring aims to compare the performance and benefits of CGM in maintaining glucose control during critical postoperative care.

Continuous Glucose Monitoring in Intensive Care Unit